BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to… Read more
BioCryst Pharmaceuticals Inc (BCRX) - Total Liabilities
Latest total liabilities as of December 2025: $633.31 Million USD
Based on the latest financial reports, BioCryst Pharmaceuticals Inc (BCRX) has total liabilities worth $633.31 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BioCryst Pharmaceuticals Inc - Total Liabilities Trend (1994–2025)
This chart illustrates how BioCryst Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BioCryst Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of BioCryst Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Innospec Inc
NASDAQ:IOSP
|
USA | $496.50 Million |
|
Boxer Retail Ltd
JSE:BOX
|
South Africa | R12.03 Billion |
|
Guangdong Advertising Co Ltd
SHE:002400
|
China | CN¥6.04 Billion |
|
Select Medical Holdings
NYSE:SEM
|
USA | $3.82 Billion |
|
Tecan Group AG
SW:TECN
|
Switzerland | CHF656.74 Million |
|
GalaxyCore Inc
SHG:688728
|
China | CN¥15.64 Billion |
Liability Composition Analysis (1994–2025)
This chart breaks down BioCryst Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -5.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioCryst Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioCryst Pharmaceuticals Inc (1994–2025)
The table below shows the annual total liabilities of BioCryst Pharmaceuticals Inc from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $633.31 Million | -34.46% |
| 2024-12-31 | $966.35 Million | -0.63% |
| 2023-12-31 | $972.49 Million | +15.14% |
| 2022-12-31 | $844.60 Million | +21.50% |
| 2021-12-31 | $695.14 Million | +96.38% |
| 2020-12-31 | $353.98 Million | +158.32% |
| 2019-12-31 | $137.03 Million | +40.39% |
| 2018-12-31 | $97.61 Million | +3.30% |
| 2017-12-31 | $94.49 Million | +7.05% |
| 2016-12-31 | $88.27 Million | +14.89% |
| 2015-12-31 | $76.83 Million | +25.46% |
| 2014-12-31 | $61.24 Million | +22.50% |
| 2013-12-31 | $49.99 Million | -13.65% |
| 2012-12-31 | $57.89 Million | -14.11% |
| 2011-12-31 | $67.40 Million | +53.38% |
| 2010-12-31 | $43.94 Million | -21.42% |
| 2009-12-31 | $55.92 Million | +46.15% |
| 2008-12-31 | $38.27 Million | -50.82% |
| 2007-12-31 | $77.81 Million | +64.40% |
| 2006-12-31 | $47.33 Million | +15.98% |
| 2005-12-31 | $40.81 Million | +1201.96% |
| 2004-12-31 | $3.13 Million | +90.08% |
| 2003-12-31 | $1.65 Million | +40.63% |
| 2002-12-31 | $1.17 Million | -48.63% |
| 2001-12-31 | $2.28 Million | -75.58% |
| 2000-12-31 | $9.35 Million | +367.27% |
| 1999-12-31 | $2.00 Million | +42.86% |
| 1998-12-31 | $1.40 Million | +16.67% |
| 1997-12-31 | $1.20 Million | -29.41% |
| 1996-12-31 | $1.70 Million | -5.56% |
| 1995-12-31 | $1.80 Million | +12.50% |
| 1994-12-31 | $1.60 Million | -- |